Articles tagged with Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that MET oncogene amplification creates a hostile environment for immunotherapy, making it ineffective in treating some lung cancers. A combination of a MET inhibitor and anti-PD1 immunotherapy was effective in treating cancers with MET amplification.
A large long-term study found that individuals with high physical activity levels and healthy sleep patterns had lower risks of death from heart disease, stroke, and cancer. Those who were physically inactive and had poor sleep quality were most at risk of dying from these causes.
New research reveals how lung cancer progression disrupts circadian glucose regulation, fueling cancer cell growth. The study identifies REV-ERB? as a key regulator and suggests targeting this protein to suppress cancer cell growth.
A study published in Journal of Thoracic Oncology found that low-dose computed tomography (LDCT) screening for primary lung cancer is associated with a lower risk of developing brain metastases. Researchers identified 1502 participants diagnosed with lung cancer between 2002 and 2009, where LDCT screening was detected versus other meth...
Researchers at Moffitt Cancer Center have developed a non-invasive method to measure PD-L1 biomarker levels in lung cancer patients using PET/CT scan images. This approach uses deep learning to predict checkpoint inhibitor outcomes, which could help determine optimal treatment strategies for patients.
Researchers at Mount Sinai Hospital discovered that early-stage lung cancer tumors hijack immune cells called tissue-resident macrophages to facilitate their invasion of lung tissue. This process allows the tumor to evade the immune system and grow into more deadly stages of cancer.
The LMO1 gene codes for a protein that regulates RNA production and is implicated in cancer formation. Researchers found that overexpression of LMO1 is associated with poor patient outcomes in different cancers. Further study of LMO1 may lead to targeted therapies for various types of cancer.
A modeling study found that schools can reopen safely with controlled community transmission and moderate mitigation strategies in place. Asymptomatic screening is one identified strategy to facilitate reopening while minimizing transmission risk.
The FDA-approved drug sotorasib has been shown to reduce tumor size and improve survival among patients with non-small-cell lung cancer caused by a specific DNA mutation. The study involved 126 patients who showed significant responses to the treatment, including 34% achieving partial response and 3% complete response.
A new study published in the Journal of Thoracic Oncology found that using traditional methods like BMI can misclassify obesity as a non-risk factor for lung cancer. The researchers measured visceral fat index through CT scans and found a clear correlation between central obesity and poor lung cancer outcomes.
A new study found that delaying lung cancer surgery for more than 12 weeks after diagnosis is associated with a higher risk of recurrence and death. Patients who underwent surgery within this time frame lived 7.5 months longer than those who delayed treatment.
The acylfulvene alkylating agent LP-184 demonstrates highly potent anticancer activity in NSCLC cell lines, correlating with PTGR1 transcript levels. It targets tumors regardless of co-occurring mutations but is especially effective in KEAP1 mutant settings.
A new AI algorithm accurately predicts lung cancer risk from low-dose CT scans, outperforming established models and human clinicians. The algorithm may aid in optimizing follow-up recommendations for lung cancer screening participants.
A new study reveals that breast cancer survivors have a 20-44% higher risk of developing new cancer diagnoses compared to healthy individuals. The research identifies specific breast cancer subtypes and diagnosis ages associated with increased risk of subsequent primary cancers.
A lack of insurance leads to worse cancer survival across the 16 most common cancers, with uninsured patients 60-64 facing significantly poorer outcomes than their older counterparts. This disparity is driven by the high costs of newer potentially lifesaving treatments, which can be unaffordable for those without insurance.
Research suggests that implementing ATS-recommended air quality standards could prevent tens of thousands of deaths, lung cancer cases, and illnesses. By meeting these standards, the US could avoid an estimated 14,650 deaths, 2,950 lung cancer cases, and 33,000 additional illnesses annually.
A retrospective study found that CT features can help select patients with stage IA non-small cell lung cancer for sublobar resection. Peritumoral interstitial thickening and pleural contact were independently associated with pathologic lymphovascular invasion, predicting recurrence-free survival after the procedure.
Researchers created a spatial atlas of early-stage lung cancer and normal lung tissue at single-cell resolution, providing insights into tumor development and immune cell interactions. The study identified CD24 as a new immunotherapy target for lung cancer treatment, correlating with poor clinical outcomes and shortened survival.
A new study by UCLA researchers identified a novel combination therapy using immune checkpoint inhibitors with ATRA to potentially overcome resistance to immunotherapy in LKB1-deficient lung cancer. The therapy led to eradication of over 70% of tumors and generated durable tumor-specific immunity.
Researchers found that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening. The study, published in JAMA Network Open, aimed to strengthen the argument for more inclusive guidelines for screening eligibility.
A study by Penn State researchers found that people who felt pleasure in a controversial celebrity's misfortune were less likely to take steps to prevent lung cancer or COVID-19. The study suggests that schadenfreude can demotivate people from taking preventive actions, having serious public health implications.
Researchers at VCU Massey Cancer Center have identified a protein called PLK3 that operates with mutated p53 genes to spur lung cancer growth. Inhibiting PLK3 has been shown to reduce tumor cell formation and proliferation in preclinical models of lung cancer.
Researchers found that patients with high levels of PDL-1 and a KRAS gene mutation lived longer when treated with immunotherapy alone compared to those without the mutation. Patients without the mutation had better survival with combination therapy, suggesting preferred treatment approaches for this patient group.
Researchers at Wake Forest School of Medicine have identified a set of new genetic markers that could lead to targeted treatments for non-small cell lung cancer. The study found that tumors with mutated KMT2 genes exhibit genetic instability, making them more sensitive to PARP inhibitors.
The cancer burden in China has undergone a paradigm shift, with rising cases of breast and lung cancers. The country's high incidence rate makes it a priority for policymakers to implement tailored preventive measures, including health education, vaccination programs, and tobacco-control policies.
A team of researchers has developed AI tools to predict which lung cancer patients will respond to immunotherapy, with the goal of improving patient outcomes and reducing costs. The study uses machine learning algorithms to analyze tissue scan patterns and identify previously unseen indicators that can inform treatment decisions.
Researchers found a novel genomic signature associated with increased risk of early death from lung cancer. Patients with high expression of these genes have indicators of immune system activity, but also suppressed T cells, which can impact treatment effectiveness.
The IASLC Molecular Database Project seeks to accelerate understanding of lung cancer biology, clinical care, and global scale. It aims to provide a platform for deeper, broader understanding of molecular testing and targeted therapy.
Two researchers from the University of Minnesota Medical School will lead a new VA-funded network to expand lung cancer screenings and research among veterans in the Upper Midwest region. The $4.5 million grant aims to increase veteran access and participation in lung cancer clinical trials, addressing barriers such as distance travel,...
The new guidelines recommend yearly low-dose CT scans for Americans aged 50-80 with a 20 pack-year smoking history or those who quit less than 15 years ago. The expanded criteria aim to reduce lung cancer disparities in Black people and women.
Updated USPSTF guidelines based on age, pack-years, and quit-years exacerbate eligibility disparities among racial and ethnic minorities. However, incorporating certain risk prediction models may help mitigate these inequalities, according to a study published in the American Journal of Roentgenology.
A new study found that a second drug targeting KRASG12C showed promising results in treating non-small-cell lung cancer (NSCLC) with this specific mutation. Nearly half of patients evaluable for clinical activity had a partial response to treatment, setting up potential future trials and combinations.
A new lymph node collection kit has been shown to improve long-term survival after curative-intent lung cancer surgery. The kit helps surgeons attain complete resection by improving pathologic nodal evaluation, leading to a significant increase in R0 resections and reduction in non-examination of lymph nodes.
Researchers discovered that glucose metabolism in tumor-associated neutrophils determines their tumor-supportive behavior in lung cancer development. Removing Glut1 from these cells reduces tumor growth rate but increases radiotherapy efficacy.
Researchers at Baylor College of Medicine have identified 25 rare genetic variants associated with increased risk of lung cancer. These variants, which include insertions and deletions, lead to genomic instability and increase DNA damage, suggesting a potential role in cancer development.
A study reveals that over one in ten lung cancer patients are unsure of their tumor type, highlighting the need for improved communication between patients and healthcare providers. Language differences and complex treatments contribute to these misunderstandings, jeopardizing patient care.
Golfers Against Cancer funds three CU Cancer Center researchers: Matthew Sikora studying genetic predispositions to ovarian cancer, Jamie Studts exploring lung cancer screening access, and Jenna Sopfe developing a standardized approach to sexual dysfunction in pediatric cancer survivors.
Researchers developed a new method to detect circulating tumor cells in NSCLC patients, identifying a CK-negative CTC population associated with metastasis and drug resistance. The use of hexokinase-2 as a biomarker revealed this novel CTC population in 50% of analyzed patients.
The new USPSTF recommendation doubles the number of eligible adults for lung cancer screening from 6.4 million to 14.5 million. However, experts argue that this expansion may not address racial inequities and highlights the need for individualized risk assessment and genetic risk models.
Experts recommend shared decision-making between patients and doctors before low-dose CT scans for lung cancer screening to ensure informed consent. The process can promote patient engagement, tobacco cessation, and screening adherence, leading to greater health equity.
A comprehensive review of lung cancer screening trials reveals both benefits and harms, leading to updated USPSTF recommendations. Screening can lower lung cancer deaths in high-risk individuals, but also leads to false positives and unnecessary procedures.
Researchers at KIST discovered that red ginseng can significantly suppress lung cancer metastasis, with components Rk1 and Rg5 showing effective inhibition. The study developed a microwave processing method to increase the concentration of these components, leading to potential anti-cancer effects.
A team led by Dr. Brian Brown is developing a CAR T-cell therapy that specifically targets immune-suppressing macrophages in tumors, clearing the way for other T cells to destroy cancer cells. The grant aims to advance this promising approach and bring new hope to patients with solid tumor cancers.
Moffitt researchers found that epithelial and mesenchymal subtypes of lung cancer cells respond differently to KRASG12C inhibitor therapy, with varying levels of sensitivity. The study suggests that targeting alternative signaling pathways, such as HER2 and FGFR1, may enhance treatment efficacy.
Researchers developed a deep learning model that accurately predicts lung cancer patients' survival expectancy, significantly better than traditional machine learning models. The model can analyze large amounts of data to understand how various factors affect lung cancer survival periods.
The NEOSTAR trial found that combination therapy produced significant clinical benefits, including higher major pathologic response rates and enhanced tumor immune cell infiltration. The treatment also triggered immunological memory, which may translate to a reduced risk of tumor relapse.
A new algorithm developed by researchers at the University of Copenhagen can detect unusual disease trajectories in COPD patients that may indicate a different diagnosis, such as lung cancer. The algorithm was trained on data from 284,000 patients and identified approximately 69,000 typical disease trajectories.
A study published in Oncotarget found that hemoglobin-based oxygen carriers increase chemotherapy effectiveness in non-small cell lung cancer. PolyHb administration attenuates tumor growth without alleviating hypoxia, suggesting a potential strategy to enhance cisplatin sensitivity.
Patients with non-small cell lung cancer who enrolled in a phase III early-stage trial showed a high rate of smoking reduction and cessation following study entry. Smoking rates were significantly lower among never-smokers, leading to improved overall survival compared to smokers.
Lung cancer is a leading cause of death in Singapore and the world, with Asian populations exhibiting distinct genetic alterations. The World Conference on Lung Cancer Singapore presented new data on EGFR mutation and TKI-drug resistance, highlighting the need for targeted treatment approaches.
The phase III CROWN study showed that lorlatinib significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC. Patient-reported outcomes also indicated comparable time to treatment deterioration for lung cancer symptoms between the two treatments.
The LCMC3 study showed that neoadjuvant atezolizumab was well tolerated and met its primary endpoint, achieving a major pathologic response rate of 21% in patients without EGFR/ALK mutations. The therapy also showed high complete resection rates and low perioperative morbidity and mortality.
A nationwide lung cancer LDCT screening study found the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker population. The study revealed that family history significantly increased lung cancer risk, and most participants had stage 0 or 1 disease.
A host immune classifier test may help guide immunotherapy treatment decisions for patients with newly diagnosed non-small cell lung cancer. The test, which measures inflammation in the body, is associated with longer overall survival and better treatment response.
The Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study demonstrated that nivolumab significantly improves overall and progression-free survival in patients with relapsed malignant mesothelioma. The treatment also showed a consistent safety profile without new adverse effects.
Researchers analyzed mRNA expression levels of molecular markers ERCC1 and thymidylate synthase in patients with resected stage II-III non-small cell lung cancer. The study found no correlation between these markers and overall survival, contradicting previous hopes for a personalized chemotherapy approach.
Researchers investigating lung cancer treatment during the pandemic found that patients with lung cancer experience higher levels of psychological distress and anxiety about accessing care. The study also revealed that patient advocacy organizations face challenges in providing support due to decreased funding.
Researchers found that combining ipilimumab with pembrolizumab did not significantly improve overall survival or progression-free survival for patients with NSCLC. The combination was also associated with greater treatment-related adverse events.
Research found that black patients diagnosed with non-small cell lung cancer are more likely to be diagnosed at an advanced stage and have lower chances of receiving surgery. Additionally, they experience significantly reduced cancer-specific survival rates compared to their white counterparts.
Two ADAURA analyses presented at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer (WCLC) Singapore support the use of Osimertinib as a new treatment strategy for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer. The data show significant disease-free surviva...